Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), a biotechnology company with a market capitalization of $1.02 billion, reported the sale of 4,000 shares of common stock over two days, totaling $46,280. The transactions occurred on March 11 and March 12, 2025, with sale prices ranging from $11.4 to $11.74 per share. These sales were executed under a Rule 10b5-1 trading plan adopted in September 2024. Following these transactions, Ma holds 2,835,260 shares indirectly through a family member. The stock, currently trading at $11.96, has shown strong momentum with a 9% gain over the past week, though InvestingPro analysis suggests the shares are currently overvalued. InvestingPro subscribers have access to 8 additional key insights about GYRE’s valuation and financial health.
In other recent news, Gyre Therapeutics announced the appointment of Ping Zhang as the lead independent director of its Board of Directors. Zhang, who has a strong financial background, will also serve on the Nominating and Corporate Governance Committee. The company also reported leadership changes at its subsidiary, Gyre Pharmaceuticals, with Songjiang Ma taking over as Chairman following Ying Luo’s resignation to focus on his role at GNI Group Ltd. Gyre Pharmaceuticals is actively advancing its pipeline in China, with ongoing clinical trials for its drug F351 and the commercialization of ETUARY® (Pirfenidone capsule), which achieved net sales of $112.1 million in 2023. The company is also working on treatments for other conditions, including COPD, PAH, and ALF/ACLF. These recent developments reflect Gyre Therapeutics’ strategic focus on expanding its clinical and commercial activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.